Author:
Cressey Tim R.,Siriprakaisil Oraphan,Klinbuayaem Virat,Quame-Amaglo Justice,Kubiak Rachel W.,Sukrakanchana Pra-ornsuda,Than-in-at Kanchana,Baeten Jared,Sirirungsi Wasna,Cressey Ratchada,Drain Paul K.
Funder
National Institute of Allergy and Infectious Diseases
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
2. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
4. TRUVADA® (emtricitabine/tenofovir disoproxil fumarate) tablets fouPIGS, Inc. Initial U.S. Approval: 2004. Theol Rev: 04/2016.
5. World Health Organization. WHO expands recommendation on oral pre- exposure prophylaxis of hiv infection (PrEP). Policy Brief, November 2015, WHO/HIV/2015.48. Geneva; World Health Organization, 2015. Accessed at:
http://apps.who.int/iris/bitstream/10665/197906/1/WHO_HIV_2015.48_eng.pdf
. Accessed 12 June 2017.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献